Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care

Not Applicable

Completed

• Conditions: Depression
• Interventions: Behavioral: Pharmaceutical care program for antidepressant treatment

• Registration Number: NCT00794196
• Lead Sponsor: Fundació Sant Joan de Déu

Brief Summary

The purpose of this study is to evaluate the impact of pharmaceutical services among patients starting a treatment with antidepressants for a diagnosis of depression. The hypothesis of the study is that pharmacist intervention can improve compliance to antidepressants and patient wellbeing.

Detailed Description

The aim of this study is to evaluate the efficacy of a support program in community pharmacy on the improvement of the compliance to antidepressants and the clinic of typical primary care patients under normal practice circumstances. That implies that the intervention is made by pharmacists without any specific requirement that work in the community pharmacies set up in the area of study and on patients following the usual medical circuit. As well, the cost of the support program is calculated in order to set the effectiveness of the program.

Study Timeline

• Study Start: 2008-10
• Study First Submitted: 2008-11-17
• Study First Submitted QC: 2008-11-17
• Study First Posted: 2008-11-19
• Primary Completion: 2011-11
• Study Completion: 2012-11
• Results First Submitted: 2016-04-13
• Results First Submitted QC: 2016-07-04
• Results First Posted: 2016-08-15
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-01
• Last Update Posted: 2016-11-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 179

Inclusion Criteria

• Clinical diagnosis for depression from a general practitioner
• Beginning a pharmacological antidepressant treatment
• Going to one of the participant community pharmacies

Exclusion Criteria

• Used antidepressant medication in the past 2 months
• Had an appointment with an specialist in mental disorders in the past 2 months
• History of psychotic or bipolar episodes
• History of drug abuse or dependency
• Cognitive impairment that not allows assessment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention Group	Pharmaceutical care program for antidepressant treatment	Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.

Primary Outcome Measures

Name	Time	Method
Adherence to Antidepressant Medication	At 3 and 6 months	Adherence to antidepressant medication was measured through Pharmacy records

Secondary Outcome Measures

Name	Time	Method
Patient Wellbeing	0, 3 and 6 months	Patient wellbeing EUROQOL5D scale is used to evaluate health-related quality of life.; The answers given to EUROQOL5D allow for the description 243 unique health states which can be converted into EQ-5D index anchored at 0 for death and 1 for perfect health.

Trial Locations

Locations (2)

Primary Care Center Gavà 1; 🇪🇸 Gava, Barcelona, Spain

Primary Care Center Doctor Bartomeu Fabres Anglada; 🇪🇸 Gavà, Barcelona, Spain